|Day Low/High||86.24 / 87.03|
|52 Wk Low/High||74.97 / 96.31|
News of Intesa's potential takeover bid extended Generali's three-day gains to 15%.
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
U.S. stocks rose early Monday as investors parsed comments from oil officials in Iran and Iraq, hinting at a production cut at next week's OPEC meeting.
Novartis is entering into talks to purchase Amneal Pharmaceuticals in a deal that could value the company at $8 billion.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
Shares of the global healthcare company, Novartis, are down after it saw its profits fall in the second quarter.
You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.
Problems with mesh products and high leverage might scare away a potential buyer.
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.
Valeant may have troubles, but Mallinckrodt is the poster child of price gouging.
U.S. futures are down ahead of the final day of the Fed's 2-day policy meeting on Wednesday.
The WEF host country has a lot to offer to investors.
Underlying support for stock prices remains positive, especially if oil prices stabilize near current levels and the dollar does not rise a lot further.
Healthcare stocks were hit hard in the third quarter after leading the S&P 500 for the first half of the year.
And four other things you need to know now.
Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.
Here are some of the best pharmaceuticals our algorithm says you should consider looking at.
Here are some of the best pharmaceutical companies, that pay high dividends, TheStreet Quant Ratings says you should consider looking at.
European markets rose Wednesday after European leaders gave Greece a Sunday ultimatum for a final rescue deal or face eviction from the single currency.
Whether it's acquiring or the acquired, Mylan is building shareholder value.
Let's take a little tour through the various equity asset classes.